The impact of early PEG-asparaginase discontinuation in young adults with ALL: A post hoc analysis of the C10403 study.
      Google Scholar   
Citation:
Blood Adv
Year:
2022
Type:
Manuscript
Funding:
NCTN
Endpoint:
Secondary
Analysis:
Primary
Data Sharing:
No-Data-Sharing
Status:
Presented/Published
Citation Status:
epub
Note:
Methodological:
No
Biospecimen:
No
SDC:
No
Book Volume:
Parents:
None
Children:
None
Program:
OGC
Primary Committee:
Leukemia
Sec. Committees:
   
Pharmas:
Enzon Pharmaceuticals  
Grants:
U10CA180821, U10CA180882, P30CA033572, UG1CA232760, UG1CA233253, UG1CA233290, UG1CA233327, UG1CA233328, UG1CA233331, UG1CA233373  
Corr. Author:
 
Authors:
                                 
Networks:
ADM403, ALLIANCE, CA043, LAPS-IL036, LAPS-IL057, LAPS-MA036, LAPS-MN026, LAPS-NC007, LAPS-NC010, LAPS-OH007, OH027   
Study
CALGB-10403
Multiple Studies, or Legacy Studies in Alliance Study:
Phases:
2
Keywords: